Kindred Biosciences Inc (NASDAQ:KIN) has been assigned a consensus rating of “Buy” from the ten ratings firms that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $20.44.

A number of analysts recently weighed in on KIN shares. HC Wainwright set a $16.00 price objective on shares of Kindred Biosciences and gave the stock a “buy” rating in a research note on Wednesday, October 31st. Cantor Fitzgerald set a $25.00 price objective on shares of Kindred Biosciences and gave the stock a “buy” rating in a research note on Monday, January 14th. B. Riley upped their price objective on shares of Kindred Biosciences from $16.00 to $21.00 and gave the stock a “buy” rating in a research note on Thursday, November 8th. BidaskClub lowered shares of Kindred Biosciences from a “buy” rating to a “hold” rating in a research note on Saturday, December 8th. Finally, Zacks Investment Research lowered shares of Kindred Biosciences from a “hold” rating to a “sell” rating in a research note on Friday, January 18th.

Shares of NASDAQ KIN traded up $0.36 during mid-day trading on Friday, reaching $10.83. The company had a trading volume of 677,801 shares, compared to its average volume of 235,594. The stock has a market cap of $367.28 million, a PE ratio of -8.80 and a beta of 0.65. Kindred Biosciences has a 52 week low of $8.05 and a 52 week high of $15.75.

In other Kindred Biosciences news, CEO Richard Chin sold 40,000 shares of the stock in a transaction dated Wednesday, January 2nd. The shares were sold at an average price of $10.57, for a total transaction of $422,800.00. Following the completion of the sale, the chief executive officer now directly owns 1,906,071 shares of the company’s stock, valued at $20,147,170.47. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Park West Asset Management Llc purchased 741,840 shares of the firm’s stock in a transaction on Friday, January 18th. The shares were purchased at an average cost of $9.50 per share, with a total value of $7,047,480.00. The disclosure for this purchase can be found here. Corporate insiders own 15.96% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the business. Morgan Stanley lifted its position in shares of Kindred Biosciences by 0.3% during the third quarter. Morgan Stanley now owns 2,168,559 shares of the biopharmaceutical company’s stock valued at $30,251,000 after buying an additional 7,438 shares during the last quarter. BlackRock Inc. raised its position in shares of Kindred Biosciences by 0.8% in the 4th quarter. BlackRock Inc. now owns 1,843,519 shares of the biopharmaceutical company’s stock valued at $20,187,000 after purchasing an additional 14,126 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Kindred Biosciences by 6.0% in the 3rd quarter. Vanguard Group Inc. now owns 1,410,014 shares of the biopharmaceutical company’s stock valued at $19,669,000 after purchasing an additional 80,023 shares during the last quarter. Vanguard Group Inc raised its position in shares of Kindred Biosciences by 6.0% in the 3rd quarter. Vanguard Group Inc now owns 1,410,014 shares of the biopharmaceutical company’s stock valued at $19,669,000 after purchasing an additional 80,023 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its position in shares of Kindred Biosciences by 2.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,382,645 shares of the biopharmaceutical company’s stock valued at $15,140,000 after purchasing an additional 32,834 shares during the last quarter. 67.08% of the stock is owned by institutional investors and hedge funds.

Kindred Biosciences Company Profile

Kindred Biosciences, Inc, a biopharmaceutical company, focuses on the development of therapies for pets. The company's product pipeline includes small molecules and biologics for a range of indications in dogs, cats, and horses. Its lead product candidates comprise Zimeta, a dipyrone injection for the control of pyrexia (fever) in horses; and Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats.

Featured Article: What is the Stochastic Momentum Index (SMI)?

Analyst Recommendations for Kindred Biosciences (NASDAQ:KIN)

Receive News & Ratings for Kindred Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.